Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 314

1.

Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects.

Cheng MR, Li Q, Wan T, He B, Han J, Chen HX, Yang FX, Wang W, Xu HZ, Ye T, Zha BB.

World J Gastroenterol. 2012 Nov 14;18(42):6076-87. doi: 10.3748/wjg.v18.i42.6076.

2.

5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model.

Cheng M, He B, Wan T, Zhu W, Han J, Zha B, Chen H, Yang F, Li Q, Wang W, Xu H, Ye T.

PLoS One. 2012;7(10):e47115. doi: 10.1371/journal.pone.0047115. Epub 2012 Oct 15.

3.

Synthesis of galactosylated chitosan/5-fluorouracil nanoparticles and its characteristics, in vitro and in vivo release studies.

Cheng M, Han J, Li Q, He B, Zha B, Wu J, Zhou R, Ye T, Wang W, Xu H, Hou Y.

J Biomed Mater Res B Appl Biomater. 2012 Nov;100(8):2035-43. doi: 10.1002/jbm.b.32767. Epub 2012 Aug 2.

PMID:
22865703
4.

Preliminary pharmacology of galactosylated chitosan/5-fluorouracil nanoparticles and its inhibition of hepatocellular carcinoma in mice.

Cheng M, Liu Z, Wan T, He B, Zha B, Han J, Chen H, Yang F, Li Q, Wang W, Xu H, Ye T.

Cancer Biol Ther. 2012 Dec;13(14):1407-16. doi: 10.4161/cbt.22001. Epub 2012 Sep 6.

5.

Glycyrrhetinic acid-modified chitosan nanoparticles enhanced the effect of 5-fluorouracil in murine liver cancer model via regulatory T-cells.

Cheng M, Xu H, Wang Y, Chen H, He B, Gao X, Li Y, Han J, Zhang Z.

Drug Des Devel Ther. 2013 Oct 25;7:1287-99. doi: 10.2147/DDDT.S52809. eCollection 2013. Retraction in: Drug Des Devel Ther. 2014;8:921.

6.

Lipoteichoic acid of Bifidobacterium in combination with 5-fluorouracil inhibit tumor growth and relieve the immunosuppression.

Xie N, Wang Y, Wang Q, Li FR, Guo B.

Bull Cancer. 2012 May;99(5):E55-63. doi: 10.1684/bdc.2012.1571.

PMID:
22522606
7.
8.

Cooperative effect of Bifidobacteria lipoteichoic acid combined with 5-fluorouracil on hepatoma-22 cells growth and apoptosis.

Guo B, Xie N, Wang Y.

Bull Cancer. 2015 Mar;102(3):204-12. doi: 10.1016/j.bulcan.2014.09.003. Epub 2015 Mar 4.

PMID:
25747889
9.

Synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and its inhibition of liver cancer characteristics in vitro and in vivo.

Cheng M, Gao X, Wang Y, Chen H, He B, Xu H, Li Y, Han J, Zhang Z.

Mar Drugs. 2013 Sep 17;11(9):3517-36. doi: 10.3390/md11093517.

10.

Effects of endogenous nitric oxide induced by 5-fluorouracil and L-Arg on liver carcinoma in nude mice.

Yin XY, Jiang JM, Liu JY, Zhu JR.

World J Gastroenterol. 2007 Dec 14;13(46):6249-53.

11.

Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.

Zhao X, Chen Q, Li Y, Tang H, Liu W, Yang X.

Eur J Pharm Biopharm. 2015 Jun;93:27-36. doi: 10.1016/j.ejpb.2015.03.003. Epub 2015 Mar 11.

PMID:
25770771
12.

The effect of calmodulin antagonist berbaminederivative-EBB on hepatoma in vitro and in vivo.

Liu J, Qi S, Zhu H, Zhang J, Li Z, Wang T.

Chin Med J (Engl). 2002 May;115(5):759-62.

PMID:
12133551
13.

Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo.

Kojiro S, Yano H, Ogasawara S, Momosaki S, Takemoto Y, Nishida N, Kojiro M.

J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 1):129-37.

PMID:
16706824
14.

Anti-hepatocarcinoma effects of 5-fluorouracil encapsulated by galactosylceramide liposomes in vivo and in vitro.

Jin Y, Li J, Rong LF, Li YH, Guo L, Xu SY.

World J Gastroenterol. 2005 May 7;11(17):2643-6.

15.

Weichang'an and 5-fluorouracil suppresses colorectal cancer in a mouse model.

Tao L, Yang JK, Gu Y, Zhou X, Zhao AG, Zheng J, Zhu YJ.

World J Gastroenterol. 2015 Jan 28;21(4):1125-39. doi: 10.3748/wjg.v21.i4.1125.

16.

Preparation of chitosan-polyaspartic acid-5-fluorouracil nanoparticles and its anti-carcinoma effect on tumor growth in nude mice.

Zhang DY, Shen XZ, Wang JY, Dong L, Zheng YL, Wu LL.

World J Gastroenterol. 2008 Jun 14;14(22):3554-62.

17.

In vitro cytotoxicity, in vivo biodistribution and antitumor activity of HPMA copolymer-5-fluorouracil conjugates.

Yuan F, Qin X, Zhou D, Xiang QY, Wang MT, Zhang ZR, Huang Y.

Eur J Pharm Biopharm. 2008 Nov;70(3):770-6. doi: 10.1016/j.ejpb.2008.06.028. Epub 2008 Jul 8.

PMID:
18656539
18.

Optimized synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and their characteristics.

Cheng M, Chen H, Wang Y, Xu H, He B, Han J, Zhang Z.

Int J Nanomedicine. 2014 Jan 24;9:695-710. doi: 10.2147/IJN.S55255. eCollection 2014.

19.

In vivo and in vitro suppression of hepatocellular carcinoma by EF24, a curcumin analog.

Liu H, Liang Y, Wang L, Tian L, Song R, Han T, Pan S, Liu L.

PLoS One. 2012;7(10):e48075. doi: 10.1371/journal.pone.0048075. Epub 2012 Oct 31.

20.

[Difference of gene expression profile in human gastric cancer grafted onto nude mice treated with WCA].

Zhao AG, Yang JK, You SF, Li T, Zhao HL, Gu Y, Tang LD.

Zhongguo Zhong Yao Za Zhi. 2007 Oct;32(19):2028-36. Chinese.

PMID:
18161298
Items per page

Supplemental Content

Write to the Help Desk